Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding

Table 1 Comparison of early transjugular intrahepatic portosystemic shunt and endoscopic therapy between two groups

Characteristics	TIPS group	ET group	P value
	(64 patients)	(62 patients)
Sex (n)			0.80
Male	42	42
Female	22	20
Age (yr)	51 (± 13)	54 (± 12 )	0.96
Cases of disease (n)			0.16
HBV	38	27
HCV	8	10
Alcohol	2	7
Other	16	18
Endoscopic manifestions (n)
Varices classification			1.00
Severe	62	61
Moderate	2	1
Complicated with peptic unlcer	4	3	1.00
Complicated with gastric dieorders due to portal hypertension	23	28	0.29
Child classification (n)			0.40
A	23	17
B	30	29
C	11	16
Child score	7.0 (± 2.0 )	8.0 (± 2.0 )	0.99
Preoperative manifestations (n)
Complicated with hepatic encephalopathy	1	5	0.20
Complicated with ascites	39	38	0.97
Compression using Sengstaken-Blakemore tube	2	2	1.00
Pre-operative laboratory parameters
Bilirubin (μmol/L)	24.03 (± 12.71)	27.94 (± 13.75)	0.19
Albumin (g/L)	32.25 (± 5.03)	30.85 (± 5.31)	0.65
PT (s)	15.80 (± 3.80)	16.30 (± 4.20)	0.40
Creatinine (μmol/L)	72.80 (± 14.8)	81.50 (± 31.00)	0.21

HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: Prothrombin time; TIPS: Transjugular intrahepatic portosystemic shunt; ET: Endoscopic therapy.